急性早幼粒细胞白血病 中国就医指南

Acute Promyelocytic Leukemia (APL) is a distinct and highly treatable subtype of acute myeloid leukemia (AML), characterized by a specific chromosomal translocation t(15;17)(q24;q21) that fuses the PML gene on chromosome 15 with the RARA gene on chromosome 17. This fusion results in the PML-RARA oncoprotein, which blocks myeloid differentiation at the promyelocyte stage and promotes uncontrolled proliferation of abnormal promyelocytes in the bone marrow and peripheral blood. Unlike other AML subtypes, APL is notable for its unique coagulopathy—often presenting with life-threatening disseminated intravascular coagulation (DIC) and severe bleeding due to premature granule release and fibrinolytic activation. Epidemiologically, APL accounts for approximately 5–10% of all adult AML cases, with an annual incidence of 0.2–0.8 per 100,000 people worldwide. It peaks in the fourth to sixth decades of life, though it can occur at any age—including childhood—and shows no significant gender predilection. While most cases are sporadic, rare associations have been reported with prior chemotherapy (especially alkylating agents or topoisomerase II inhibitors), ionizing radiation exposure, and possibly certain environmental toxins—but no strong inherited genetic risk factors are established. APL is not linked to common lifestyle risks like smoking or diet. The disease onset is typically abrupt, with symptoms including fatigue, pallor, petechiae, ecchymoses, gingival bleeding, epistaxis, menorrhagia, and, in severe cases, intracranial or pulmonary hemorrhage. Fever and infection may occur secondary to neutropenia. Prompt diagnosis—via peripheral blood smear, bone marrow aspiration, cytogenetics, and PML-RARA molecular testing—is critical, as untreated APL carries a mortality rate exceeding 90% within days to weeks due to hemorrhagic complications. With modern targeted therapy, however, cure rates exceed 90% in compliant patients. Quality of life (QoL) impact is substantial but time-limited: initial hospitalization involves intensive supportive care (platelet transfusions, antifibrinolytics, ICU monitoring), causing acute physical and psychological distress. During induction, patients experience retinoic acid syndrome (fever, respiratory distress, weight gain, renal dysfunction), requiring corticosteroids and close surveillance. Maintenance therapy (oral ATRA + low-dose chemotherapy) lasts several months and may cause dry skin, headache, hyperlipidemia, and mild hepatotoxicity—yet most patients resume full functional status post-remission. Psychosocial burden includes anxiety around relapse, treatment-related infertility concerns (especially in younger adults), and financial strain from prolonged outpatient follow-up. Nevertheless, APL stands as a paradigm of precision oncology—where rapid diagnosis, risk-stratified therapy, and multidisciplinary hematologic support converge to transform a once-fatal emergency into a routinely curable malignancy.

# 急性早幼粒细胞白血病（APL）治疗方案与费用明细（血液科）

一、非手术/药物治疗方案（一线标准方案）

• •适用人群：初诊、低中危（WBC＜10×10⁹/L）、无严重凝血障碍者
• •方案：全反式维甲酸（ATRA）+砷剂（三氧化二砷，ATO）联合诱导+巩固+维持治疗（总疗程约6–12个月）
• •费用明细（公立三甲医院，RMB）：

- ATO注射液（静脉，2个疗程）：¥18,000–¥25,000 - 凝血功能监测（每周）+骨髓检查（诱导后/巩固前/维持期）：¥3,200–¥5,000 - 支持治疗（成分输血、抗生素、升白针等）：¥8,000–¥22,000

二、强化/挽救性治疗方案（高危/复发/耐药）

• •适用人群：WBC≥10×10⁹/L、FLT3-ITD突变、ATO耐药或复发患者
• •方案：ATRA+ATO+化疗（如IDA/阿糖胞苷）±靶向药（吉瑞替尼，限FLT3突变）
• •费用明细（RMB）：

- 强化化疗+严密监护（ICU级支持）：¥35,000–¥68,000/周期 - 复发后微小残留病（MRD）动态监测（流式/PCR）：¥2,800–¥4,500/次

三、异基因造血干细胞移植（根治性方案）

• •适用人群：二次复发、持续MRD阳性、高危基因型（如PML-RARA复杂变异）
• •全套费用（含预处理、移植、+100天支持）：¥320,000–¥480,000（不含供者动员费）
• •术前检查（HLA配型、心肺功能、感染筛查等）：¥6,500–¥9,200

方案快速选择指南

• •预算有限/初诊低危：首选ATRA+ATO标准方案（总费用约¥35,000–¥65,000）
• •高危/复发但未达移植指征：强化化疗+靶向药（总费用¥80,000–¥180,000）
• •复发难治/持续MRD阳性：及时评估移植（总投入¥330,000–¥500,000）